Heterozygous Familial Hypercholesterolemia Clinical Trial
Official title:
EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia
Despite the availability of several classes of very effective drugs available to treat heterozygous Familial Hypercholesterolemia (HeFH), there remains a large unmet medical need for new, effective and well tolerated therapies. There are a number of therapies given on a chronic basis to reduce long term risk, such as statins, fibrates, niacin, omega 3 fatty acids, resins, cholesterol absorption inhibitors and antiplatelet or anticoagulant drugs, but subjects with heterozygous Familial Hypercholesterolemia remain at high risk for cardiovascular events. There is still a need for acute therapies that can lead to rapid pacification of unstable plaque in order to reduce the risk of these events. This study will assess the effects of CER-001 , a recombinant human Apo-A-1 based HDL mimetic, on indices of atherosclerotic plaque progression and regression as assessed by 3Tesla MRI (3TMRI)and intravascular ultrasound (IVUS) evaluations in patients with HeFH.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03563547 -
Effects of Soy Protein on Cholesterol Levels in Children Affected With Familial Hypercholesterolemia
|
N/A | |
| Terminated |
NCT03694197 -
Long Term Safety Study of PRALUENT
|
Phase 4 | |
| Active, not recruiting |
NCT04759534 -
Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia
|
Phase 3 | |
| Completed |
NCT01968980 -
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
|
Phase 3 | |
| Completed |
NCT00171236 -
Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia
|
Phase 3 | |
| Completed |
NCT03397121 -
Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)
|
Phase 3 | |
| Completed |
NCT04173793 -
A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
|
Phase 2 | |
| Not yet recruiting |
NCT06164730 -
A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
|
Phase 1 | |
| Completed |
NCT02326220 -
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
|
Phase 3 | |
| Completed |
NCT02392559 -
Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders
|
Phase 3 | |
| Completed |
NCT02460159 -
A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)
|
Phase 3 | |
| Terminated |
NCT01583647 -
A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)
|
Phase 1 | |
| Active, not recruiting |
NCT05398029 -
A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease
|
Phase 1 | |
| Completed |
NCT00706849 -
Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease
|
Phase 3 | |
| Completed |
NCT04666298 -
Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C
|
Phase 2 | |
| Completed |
NCT03038022 -
Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
|
Phase 2 | |
| Completed |
NCT01576484 -
Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)
|
Phase 2 | |
| Terminated |
NCT00151788 -
Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.
|
Phase 2/Phase 3 | |
| Completed |
NCT05325203 -
A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).
|
Phase 3 | |
| Completed |
NCT01709500 -
Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)
|
Phase 3 |